Brian F. Chapin, MD
Department of Urology, Division of Surgery
About Dr. Brian F. Chapin
Dr. Brian Chapin is a Professor in the Department of Urology at The University of Texas MD Anderson Cancer Center. He provides complete care for men with Prostate Cancer. He performs counselling, screening, diagnostics and open surgery and minimally invasive/robotic surgery, for patients with prostate cancer. His major clinical focus is on the treatment of high risk- localized, locally advanced and metastatic prostate cancers. He has active clinical research protocols developing the integration of surgical, radiation and medical therapies in the treatment of advanced prostate cancer. Dr. Chapin is involved with the basic science/translational research program at M.D Anderson, which is attempting to identify predictive signatures for identifying which patients with advanced prostate cancer will benefit most from specific therapies. Using a comprehensive multimodality approach to this disease, Dr. Chapin’s goal is to ease suffering and prolong survival in men with advanced prostate cancer.
Present Title & Affiliation
Primary Appointment
Professor, Urology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Urology, The University of Texas MD Anderson Cancer Center, Houston, TX
Director of Clinical Research, Urology, The University of Texas MD Anderson Cancer Center, Houston, TX
Fellowship Program Director, Urology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2004 | Georgetown University School of Medicine, Washington, DC, US, MD |
| 2000 | Siena College, Loudonville, New York, US, Biology, BS |
| Kelley School, US, EMBA |
Postgraduate Training
| 2010-2012 | Clinical Fellowship, Urologic Oncology, UT MD Anderson Cancer Center, Houston, Texas |
| 2006-2009 | Clinical Residency, Urology, Massachusetts General Hospital, Boston, Massachusetts |
| 2005-2006 | Clinical Residency, General Surgery, Massachusetts General Hospital, Boston, Massachusetts |
| 2004-2005 | Clinical Internship, General Surgery, Massachusetts General Hospital, Boston, Massachusetts |
Licenses & Certifications
| 2021 | Drug Enforcement Administration Registration |
| 2014 | American Board of Urology |
| 2013 | Texas Department of Public Safety Registration |
| 2012 | Texas Medical Board |
Experience & Service
Administrative Appointments/Responsibilities
Rotation Site Director, Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present
Other Professional Positions
ACCRL Faculty Advisor, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - 2027
Vice-Chair of the Prostate Cancer Sessions, SUO 2022 Scientific Program Planning Committee, San Diego, CA, 2022 - Present
Member of Expert Consensus Panel, Digital Solutions R&D at Johnson and Johnson, Virtual, 2022 - Present
Member, Diagnostic Imaging CABI Internal Advisory Board (IAB), Virtual, 2021 - Present
Representative of UT MD Anderson Cancer Center, NCCN Prostate Cancer Panel, Houston, TX, 2021 - Present
Steering Committee Member, Theranostics Program Development and Operations Committee (PDOC), Virtual, 2021 - Present
Consultant, Blue Earth Diagnostics, Dallas, Texas, 2019 - Present
Consultant, Janssen Scientific Affairs, LLC, Phoenix, AZ, 2018 - Present
Member, Education Program Directors Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present
Member, Program Evaluation Committee, The University of Texas Health Science Center, Houston, TX, 2016 - Present
Extramural Institutional Committee Activities
Chair of the Prostate Organ Site Committee, SUO-CTC Prostate Committee, Society of Urologic Oncology, 2026 - Present
Division of Surgery Representative, PRS Faculty Compensation & Benefit Advisory Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Professionalism Ambassador, Division of Surgery, The University of Texas MD Anderson Cancer Center, 2023 - Present
Division Professionalism Ambassador (DPA), representing the Division of Surgery, Center for Professionalism Support & Success (CPSS), The University of Texas MD Anderson Cancer Center, 2023 - Present
Committee Rep, OR Advisory Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Division of Surgery Representative, Clinical Term-Tenure/Term-Tenure Track Hiring Panel, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Navigation Task Force, The University of Texas MD Anderson Cancer Center, 2021 - Present
Elected Member Representative for Surgery, PRS Clinical Revenue Cycle, The University of Texas MD Anderson Cancer Center, 2021 - Present
Advisory Council, Clinical Research Leaders, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Trainee Coverage Commuter, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Trainee Benefits Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, NCTN UG1 LAPS Grant Executive Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Awards Committee Chair, SWOG Genitourinary Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Operational Priority - Recruitment, Retention and Development Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, GME Program Directors Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Member, Division of Surgery Task Force on Defining Educational Effort, The University of Texas MD Anderson Cancer Center, 2015 - Present
Member, Residency Clinical Competency Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present
Non-Voting Member, General Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present
Member, Clinical Competency Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present
Member, Surgical Education Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present
Member, Education Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present
Editorial Activities
Associate Editor, European Urology, 2023 - Present
Oncology Senior Consultant, AUA CORE Curriculum - Oncology, Urinary Diversion and Adrenal, 2019 - 2022
Guest Editorship, Current Opinions in Urology, 2019
Oncology Senior Editor, AUA CORE Curriculum - Oncology, Urinary Diversion and Adrenal, 2018 - 2022
Guest Editorship, Current Opinions in Urology, 2017
Honors & Awards
| 2025 - Present | The University of Texas System Kenneth I. Shine, M.D., Academy of Health Science Education, The University of Texas System |
| 2025 - 2026 | Department of Urology, Dr. Colin P. N. Dinney Distinguished Urologic Oncology Service Award, UT MD Anderson Cancer Center |
| 2022 | President's Recognition of Faculty Excellence, The University of Texas MD Anderson |
| 2022 | Nomination- The Shine Academy 2022 Cycle (2), UT Academy of Health Science Education |
| 2022 | Nomination- The UT System Regents' Outstanding Teaching Award (ROTA), The University of Texas MD Anderson, Division of Education and Training |
| 2019 | SUO 2019 Young Investigator Award, SUO Award Committee |
| 2016 - 2017 | Teacher Of The Year, UT MD Anderson Cancer Center |
| 2015 | Distinguished Educator Award, UT MD Anderson Cancer Center |
| 2011 | Merit Award. Genitourinary Cancer Symposium (GU ASCO), American Society of Clinical Oncology |
| 2011 | Best of Posters AUA/JUA: Post-operative Complications from Cytoreductive Nephrectomy after Pre-surgical Targeted Therapy for Metastatic Renal Cell Carcinoma, AUA |
| 2010 - 2011 | American Urologic Association Foundation Research Scholarship, AUA |
| 2007 | Harvard Medical School Resident Teaching Award, Massachusetts General Hospital |
| 2007 | Partners in Excellence Award, Massachusetts General Hospital |
| 2004 | Cum Laude, Georgetown University School of Medicine |
| 2000 | Summa Cum Laude, Siena College, Loundonville, New York |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2021. Research Discussion - GU New Research. Conference. MD Anderson Cancer Network. Houston, TX, US.
- 2021. MD Anderson Multidisciplinary Care Discussion Panel - Urology. Conference. MD Anderson Cancer Network. Houston, TX, US.
Regional Presentations
- 2025. Biochemical recurrence work up and Salvage Therapy for prostate cancer. Invited. SSUS 65th Annual Conference. Irving, Texas, US.
- 2025. Neoadjuvant Therapy in HR Prostate Cancer: Where are We Now?. Invited. University of Texas Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, Texas, US.
- 2025. Session 6: Urological Oncology. Invited. 21st Oncology Updates: Advances and Controversies. Colorado Springs, CO, US.
- 2024. Session VIII: Collaboration Across UT System. Conference. UT MD Anderson Cancer Center. Austin, TX, US.
- 2024. Session 6: Urology. Invited. 20th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2023. Novel Imaging and Theranostics in Prostate Cancer. Conference. UT MD Anderson Cancer Center. Steamboat Springs, CO, US.
- 2023. Panel Q&A and Christopher Wood Memorial Case Presentation. Conference. MD Anderson Cancer Center. Steamboat Springs, CO, US.
National Presentations
- 2025. Prostate Cancer Session 1 - Case II: High Risk Localized Prostate Cancer. Invited. 26th Annual Meeting of the Society of Urologic Oncology - SUO. Phoenix, Arizona, US.
- 2025. Director's Retreat - Career Development. Invited. 26th Annual Meeting of the Society of Urologic Oncology - SUO. Phoenix, Arizona, US.
- 2025. Prostate Cancer Block: Dilemmas, Tips and Tricks - Keynote Lecture: Salvage After Failed Local Therapy. Invited. 104th Annual Meeting of the South Central Section of AUA. Orlando, Florida, US.
- 2025. Prostate Cancer Block: Dilemmas, Tips and Tricks - Interactive Panel Session with Audience Discussion. Invited. 104th Annual Meeting of the South Central Section of the AUA. Orlando, Florida, US.
- 2025. Prostate Cancer: Advances (including Drug Therapy) III. Invited. AUA 2025. Las Vegas, NV, US.
- 2025. Tips and Tricks for Radical Prostatectomy via Video Clips. Invited. Aspen Urological Conference. Aspen, Colorado, US.
- 2024. Updates in Neoadjuvant therapy trials for Prostate Cancer. Invited. Sixth International Prostate Cancer Symposium and World Congress of Urologic Oncology. New York, NY, US.
- 2024. Session V- Debates and Discussion - Limited vs Extended Lymphadenectomy (extended). Panelist. Sixth International Prostate Cancer Symposium and World Congress of Urologic Oncology. New York, NY, US.
- 2024. From Conception to Publication: Nuts and Bolts of Trial Design and Development - Session II - Surgical & Multidisciplinary RCT. Invited. 25th Annual Meeting of the Society of Urologic Oncology. Dallas, Texas, US.
- 2024. Academic Urology Forum - Forging a Career as a Surgeon-Scientist: Success, Challenges and Pitfalls. Panelist. 103rd Annual Meeting of the South Central Section of the AUA. Colorado Springs, CO, US.
- 2024. Educators Block. Invited. 103rd Annual Meeting of the South Central Section of the AUA. Colorado Springs, CO, US.
- 2024. Educators Block - Recruiting Qualified Residents in the New Era. Panelist. 103rd Annual Meeting of the South Central Section of the AUA. Colorado Springs, CO, US.
- 2024. Prostate Cancer: Advanced (Includung Drug Therapy) II. Conference. Moderator. San Antonio, TX, US.
- 2024. Legal Advice And Pitfalls In Medicine. Panelist. 2024 Mayo Clinic Urology Review. Lahaina, HI, US.
- 2024. Management Of Metastatic Prostate Cancer: Where Are We And Where We Are We Going?. Panelist. 2024 Mayo Clinic Urology Review. Lahaina, HI, US.
- 2023. General Scientific Program. Prostate Cancer Session 1. Invited. Speaker. Washington, DC, US.
- 2023. SUO/YUO Symposium on Clinical Research & Clinical Trials Program, Tips for Getting Started- What's Important in Getting Started. Conference. Speaker. Washington, DC, US.
- 2023. Prostate Cancer Course Program - Local Therapy. Invited. Speaker. Washington, DC, US.
- 2023. Health Services Research Podium Session. Invited. Moderator. Amelia Island, FL, US.
- 2023. Prostate Cancer. Invited. Speaker. Aspen, CO, US.
- 2023. Local Therapy in Metastatic Prostate Cancer. Invited. Speaker. Aspen, CO, US.
- 2023. Evaluation and Treatment of Biochemical Recurrence. Invited. Speaker. Aspen, CO, US.
- 2023. The Current Status of PSMA PET Imaging in Prostate Cancer. Invited. Speaker. Aspen, CO, US.
- 2023. Metastasis Directed Therapy in Oligometastatic Prostate Cancer. Invited. Speaker. Aspen, CO, US.
- 2023. USPROST8CON. Invited. Faculty Member. San Francisco, CA, US.
- 2022. Robot-Assisted Salvage Prostatectomy. Invited. Speaker. New York, NY, US.
- 2022. Prostate Cancer Session II. Invited. Session Chair. San Diego, CA, US.
- 2022. Prostate Cancer Session I. Invited. Session Chair. San Diego, CA, US.
- 2022. PSMA and Prostate Cancer. Invited. Session Chair. San Diego, CA, US.
- 2022. Cancer Podium Session. Invited. Moderator. Coronado, CA, US.
- 2022. International Prostate Forum - Session II: Advances in Diagnostics. Invited. Moderator. New Orleans, LA, US.
- 2022. Prostate Cancer: Advanced (Including Drug Therapy) III. Invited. Moderator. New Orleans, LA, US.
- 2022. Panel Discussion: Active Surveillance for Intermediate Risk Prostate Cancer: When and How?. Invited. Panelist. San Juan, PR, US.
- 2022. State-of-the-Art Lecture: Optimizing Therapy for Locally Advanced Prostate Cancer. Invited. Guest Speaker. San Juan, PR, US.
- 2022. Molecular Profiling of Prostate Tissue: When and Which One?. Invited. 2022 Mayo Clinic Urology Review. Koloa, HI, US.
- 2021. Primary Tumor Treatment in the setting of mCSPC. Invited. 22nd Annual Meeting of the Society of Urologic Oncology. Virtual - Orlando, FL, US.
- 2021. Cooperative Group Trials in Urologic Oncology - How Can We Get Involved?. Invited. SUO YUO Webinar Series. Virtual, US.
- 2021. Panel Discussion: Urology Fellowships: Starting Them, Funding Them, and Recruiting Top Candidates. Invited. Speaker. Scottsdale, AZ, US.
- 2021. SWOG S1802: Is There a Benefit for Local Therapy in Metastatic Prostate Cancer?. Invited. Speaker. Scottsdale, AZ, US.
- 2021. Panel Discussion/Q&A: Achieving Equipoise: Is a Randomized, Controlled Trial Feasible?. Invited. Panelist. Las Vegas, NV, US.
- 2021. State of the Art Lecture: Personalized Medicine in the Management of Prostate Cancer Across the Patient Care Continuum. Invited. Speaker. Las Vegas, NV, US.
International Presentations
- 2025. Biochemical Relapse Of Prostate Cancer After Primary Local Therapy. Invited. John Fitzpatrick Irish Genitourinary Cancer Conference. Dublin, IE.
- 2025. Local Therapy With Node Positive Or Overt Metastatic Prostate Cancer. Invited. John Fitzpatrick Irish Genitourinary Cancer Conference. Dublin, IE.
- 2025. Medical writing for urologists: An interactive workshop on how to write, publish and promote the “perfect” manuscript - Contextualising results and crafting impactful conclusions in discussion. Invited. EAU25. Madrid, ES.
- 2025. Thematic Session - Clinically relevant questions in the management of advanced, hormone-sensitive prostate cancer - Management of locally-advanced prostate cancer: What is the standard of care in 2025? - Intensified approaches with surgery. Invited. EAU25. Madrid, ES.
- 2024. Game Changing Session - Prostate biopsy: Which is best?. Panelist. EAU24. Paris, FR.
- 2024. ESU Course 20 - Medical writing for urologists: An interactive workshop on how to write, publish and promote the “perfect” manuscript - Contextualising results and crafting impactful conclusions in discussion. Invited. EAU24. Paris, FR.
- 2024. Plenary Session-Controversies on GU cancer staging: Is it only imaging? - Are biomarkers better?. Invited. EAU24. Paris, FR.
- 2023. Debate: RARP with Margin Positive - Salvage Treatment. Invited. Speaker. Taipei, TW.
- 2023. Video of Robotic Surgery: Strategy of Continence in RARP. Invited. Speaker. Taipei, TW.
- 2023. Interactive Session" Oligiometastatic Prostate Cancer - Current Management Strategies and Role of PET Imaging. Invited. Co-Chair. Istanbul, TR.
- 2023. Moderated Oral ePoster Session 10: Prostate Cancer - Clinical Advances, Prostate Cancer - Clinical Localized and Miscellaneous (Cancer Related). Invited. Moderator. Istanbul, TR.
- 2022. Role of Radical Prostatectomy in Oligometastatic Prostate Cancer. Invited. Invited Speaker. Montreal, CA.
- 2022. Biochemical Recurrence, Salvage Radiotherapy and MDT. Invited. Invited Speaker. Virtual Meeting, US.
- 2021. Can Focal Therapy Replace Radical Therapy for Prostate Cancer? Against Focal Therapy?. Invited. Prostate Cancer Session. Vienna, AT.
- 2021. Surgical and Radiation Treatment in ‘de novo’ Metastatic Prostate Cancer. Invited. Member - Congress Scientific Committee and Speaker. Sanliurfa, TR.
- 2021. Biochemical Recurrence and Salvage Radiotherapy. Invited. Speaker. Buenos Aires, AR.
- 2021. The Clinical Utility of Axumin PET in Biochemical Recurrence. Invited. Axumin Lecture Tour. Taiwan, CN.
- 2021. Cytoreductive Prostatectomy in the Oligometastatic Patient. Invited. Next Frontiers to Cure Cancer-2021. Sao Paulo, BR.
- 2021. The Role of Surgery in High Risk Prostate Cancer. Invited. Invited Speaker. Niagara Falls, CA.
Formal Peers
- 2025. Preparing for a Career in Academic Urology; Trials, Tribulations, and Finding Fulfillment. Charlotte, NC, US.
- 2025. The Role of Local Therapy in Metastatic Prostate Cancer. Charlotte, NC, US.
- 2025. Local Therapy in Metastatic Prostate Cancer. Vancouver, CA.
- 2025. Preparing for a Career in Academic Urology: Trials, Tribulations, and Finding Fulfillment. Vancouver, CA.
- 2023. PET Use In Prostate Cancer Diagnosis and Treatment. Visiting. Houston, TX, US.
- 2022. Indications for PET Imaging. Invited. New York, NY, US.
- 2022. Indications for PET Imaging. Visiting. New York, NY, US.
- 2022. Local Management for Oligometastasis. Visiting. New York, NY, US.
- 2022. Local Management for Oligometastasis. Invited. New York, NY, US.
- 2021. Local Therapy in Metastatic Prostate Cancer: S1802. Visiting. Virtual, US.
- 2021. Role of the Urologist in Recurrent Prostate Cancer. Visiting. Houston, TX, US.
- 2021. The Role of Local Therapy in Metastatic Prostate Cancer. Visiting. Atlanta, GA, US.
- 2021. Treatment of the Primary Tumor in Metastatic Prostate Cancer. Visiting, US.
- 2021. The Role of Surgery and Radiation in Metastatic Prostate Cancer. Visiting. New York, NY, US.
- 2021. The Role of the Urologist in Recurrent Prostate Cancer. Visiting. Aurora, CO, US.
- 2021. Local Therapy in Metastatic Prostate Cancer. Visiting. Augusta, GA, US.
- 2020. 21st Future Directions in Urology Symposium (FDUS 21) Think Tank. Invited, US.
- 2020. Extraprostatic extension - Surgical perspective. Invited, US.
- 2020. Prostate Cancer Foundation Global Knowledge Exchange on Oligometastatic Prostate Cancer. Invited, US.
- 2020. Gender Equality in Surgery and Surgical Training. Visiting. Houston, TX, US.
- 2019. Management of Lymph Node-Positive Prostate Cancer and Neoadjuvant Systemic Therapy in Localized Prostate Cancer. Invited. New York, NY, US.
- 2019. Medical Crossfire®: Localized Therapy for Metastatic HSPC? Surgery Versus RT - Evidence for Surgery. Invited. New York, NY, US.
- 2018. Management of Lymph Node Positive Prostate Cancer and Neoadjuvant Systemic Therapy in Localized Prostate Cancer. Invited. New York, NY, US.
- 2018. Urology: Changing Paradigm of Therapy and Changing Technologies. Visiting. Vedra Beach, FL, US.
- 2018. Local Therapy in Metastatic Prostate Cancer. Visiting. Mineola, NY, US.
- 2018. Local Therapy in Metastatic Prostate Cancer. Visiting. Boston, MA, US.
- 2017. Treatment of the Prostate in M1 Prostate Adenocarcinoma. Visiting. New Orleans, LA, US.
- 2016. Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. Visiting. Galveston, TX, US.
- 2016. Definitive Treatment of Primary Tumor in Metastatic Prostate Cancer. Visiting. Houston, TX, US.
- 2016. Control of the Primary Tumor in Node positive and Metastatic Prostate Cancer. Visiting. Baltimore, MD, US.
- 2015. Treatment of Localized Prostate Cancer. Visiting. Houston, TX, US.
- 2015. Local Treatment in Node Positive and Metastatic Prostate Cancer. Visiting. Houston, TX, US.
- 2015. Control of the Primary Tumor in Metastatic Prostate Cancer. Visiting. Houston, TX, US.
- 2014. Management of the Spectrum of Prostate Cancer. Invited. Duluth, MN, US.
- 2014. Prostate Cancer. Visiting. Houston, TX, US.
- 2014. Treatment of the Primary Tumor in Node Positive and Metastatic Prostate Cancer. Visiting. Boston, MA, US.
- 2014. Advances in Prostate Cancer. Invited. The Woodlands, TX, US.
- 2013. Update on Prostate Screening and Therapy. Invited. El Paso, TX, US.
- 2013. Critical Oncologic Aspects of Surgery in Bladder Cancer. Visiting. Houston, TX, US.
- 2013. Treatment of the Primary Tumor in Node Positive and Metastatic Prostate Cancer. Visiting. New Orleans, LA, US.
- 2013. Treatment of the Primary Tumor in Node Positive and Metastatic Prostate Cancer. Visiting. Houston, TX, US.
Grant & Contract Support
| Date: | 2022 - 2026 |
| Title: | Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1-R01-CA257610 |
Selected Publications
Peer-Reviewed Articles
- Chapin, BF, Smaldone, MC, Zurita-Saavedra, A, Wang, RJ, Cooperberg, MR, Gleave, ME, Delacroix, SE, Davis, JW, Pettaway, CA, Pisters, LL, Adibi, M, Chery, LJ, Papadopoulos, JN, Ward, JF, Gregg, JR, Navai, N, Corn, P, Subudhi, SK, Logothetis, CJ, Kuban, DA, Nguyen, Q, Tang, C, Choi, S, Hoffman, K, Lozano, M, Elsheftawi, M, Achim, M, Zhao, Y, Ramesh, N, Sei, E, Navin, N, Nogueras Gonzalez, G, Wang, X, Zhu, K, Troncoso, P, Zhang, M, McGuire, SE, Aparicio, A. A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. European urology 90(2):125-136, 2026. e-Pub 2026. PMID: 41833492.
- Smith, MR, Lawen, T, Garcia, RS, Pyo, J, Hahn, AW, Frigo, DE, Ma, HY, Wei, P, Robert, M, Chery, LJ, Chapin, BF, Daniel-MacDougall, CR, Pettaway, CA, Gregg, JR. The intersection of race and adiposity in prostate cancer. European Journal of Cancer Prevention 35(4):362-369, 2026. e-Pub 2026. PMID: 41117610.
- Spratt, DE, Srinivas, S, Adra, N, Ahmed, B, An, Y, Bitting, RL, Chapin, BF, Cheng, HH, Cho, SY, D'Amico, AV, Desai, NB, Dorff, TB, Eastham, JA, Farrington, TA, Gao, X, Gupta, S, Ippolito, JE, Karnes, RJ, Kishan, AU, Kuettel, M, Lang, JM, Lee, D, Lotan, TL, McDonald, A, Morgan, TM, Pessoa, R, Rais-Bahrami, S, Roach, M, Robin, T, Rosenfeld, S, Scarpato, KR, Seibert, TM, Shabsigh, A, Szmulewitz, R, Teply, BA, Tward, JD, Valicenti, RK, VanderWeele, D, Wong, JK, Kovach, E, Freedman-Cass, DA. NCCN Continuing Education. JNCCN Journal of the National Comprehensive Cancer Network 24(5):141-149, 2026. e-Pub 2026. PMID: 42134408.
- Lawen, T, Garcia, RS, Smith, MT, Pyo, J, Higgason, N, Robert, M, Chapin, BF, Chery, LJ, Davis, JW, Ward, JF, Pisters, LL, Pettaway, CA, Hahn, AW, Frigo, DE, Wei, P, Daniel-MacDougall, CR, Gregg, JR. Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance. Journal of Urology Publish Ahead of Print, 2026. e-Pub 2026. PMID: 41662578.
- Garcia, RS, Daniel-MacDougall, CR, Hwang, C, Levy, E, Smith, MR, Cho, D, Frigo, DE, Hahn, AW, Ma, HY, Robert, M, Pettaway, CA, Chapin, BF, LaRue, D, Canfield, S, Wargo, J, Wei, P, McNeill, LH, Gregg, JR. Implementing intervention mapping to tailor the evidence-based PREDIMED intervention for medically underserved prostate cancer patients. Translational behavioral medicine 16(1), 2026. e-Pub 2026. PMID: 42258524.
- Spratt, DE, Srinivas, S, Adra, N, Ahmed, B, An, Y, Bitting, RL, Chapin, BF, Cheng, HH, Cho, SY, D'Amico, AV, Desai, NB, Dorff, TB, Eastham, JA, Farrington, TA, Gao, X, Gupta, S, Ippolito, JE, Jeffrey Karnes, R, Kishan, AU, Kuettel, M, Lang, JM, Lee, D, Lotan, TL, McDonald, A, Morgan, TM, Pessoa, R, Rais-Bahrami, S, Roach, M, Robin, T, Rosenfeld, S, Scarpato, KR, Shabsigh, A, Szmulewitz, R, Teply, BA, Tward, JD, Valicenti, RK, VanderWeele, D, Wong, JK, Kovach, E, Freedman-Cass, DA. Prostate Cancer, Version 3.2026. JNCCN Journal of the National Comprehensive Cancer Network 23(11):469-493, 2025. e-Pub 2025. PMID: 41213253.
- Sherry AD, Siddiqui BA, Haymaker C, Fellman BM, Medina-Rosales MN, Bathala TK, Wang S, Liu S, Seo A, Hara K, Lu H, Troncoso P, Chun SG, Ha CS, Mayo LL, Mok H, Park RJ, Chapin BF, Phillips RM, Deek MP, Kovitz CA, Aparicio A, Zurita AJ, Pilie PG, Cohen L, Choi SL, Reuben A, Tran PT, Corn PG, Subudhi SK, Tang C. Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial. Eur Urol 88(5):496-509, 2025. e-Pub 2025. PMID: 40750497.
- Fang, A, Chapin, BF, Shi, CW, Sun, J, Qayyum, A, Kundra, V, Corn, P, Kuban, DA, Ravizzini, G, Surasi, DS, Ma, J, Bathala, TK. Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer. Prostate Cancer and Prostatic Diseases 28(3):761-766, 2025. e-Pub 2025. PMID: 39289537.
- Zurita AJ, Tidwell RS, Chapin BF, Harris DR, Zhang M, Pisters LL, Aparicio A, Araujo JC, Arce-Gallego S, Zhu K, Lozano ML, Pagliaro L, Mateo J, Logothetis C, Troncoso P, Davis JW. Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis. Eur Urol Oncol 8(4):1010-1019, 2025. e-Pub 2025. PMID: 40651932.
- Bsteh, D, Buckley, J, Mitchell, S, Ostrow, D, Parmentier, JH, Jahan, S, Sadis, S, Smith, J, NI, J, Peng, X, McConkey, DJ, Dorff, TB, Lerner, SP, Aparicio, A, Chapin, BF, Duddalwar, V, Triche, T, Goldkorn, A. Combined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC). Journal of Clinical Oncology 43:e17111-e17111, 2025. e-Pub 2025.
- Hassanzadeh, CJ, Mohamad, O, Bruno, TL, Wang, L, Kudchakar, R, Bathala, TK, Sanders, JW, Mok, H, McGuire, SE, Kuban, DA, Hoffman, K, Nguyen, Q, Park, RJ, Thames, HD, Corn, P, Chapin, BF, Choi, S, Tang, C, Frank, SJ. Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences. Brachytherapy 24(2):231-237, 2025. e-Pub 2025. PMID: 39755443.
- Gregg, JR, Newcomb, LF, Wu, R, Dennison, JB, Davis, JW, Pettaway, CA, Pisters, L, Ward, JF, Chapin, BF, Chery, LJ, Urkmez, A, Fang, A, Higgason, N, Troncoso, P, Daniel-MacDougall, CR, Logothetis, CJ, Thompson, TC, Hahn, AW, Liu, M, Zheng, Y, Lin, DW, Hanash, SM, Irajizad, E, Fahrmann, JF. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomarker Research 12(1), 2024. e-Pub 2024. PMID: 39522029.
- Sosa, A, Rooney, MK, Thames, HD, Sanders, JW, Swanson, DM, Choi, S, Nguyen, Q, Mok, H, Kuban, DA, Ron Zhu, X, Shah, SJ, Mayo, LL, Hoffman, K, Tang, C, McGuire, SE, Sahoo, N, Zhang, X, Lee, AK, Pugh, T, Mahmood, U, Davis, JW, Chapin, BF, Corn, P, Kudchadker, R, Ausat, N, Frank, SJ. Proton therapy toxicity outcomes for localized prostate cancer. Clinical and Translational Radiation Oncology 48, 2024. e-Pub 2024. PMID: 39188999.
- Lowentritt, B, Jani, AB, Helfand, BT, Uchio, E, Morris, MA, Michalski, JM, Chau, A, Davis, P, Chapin, BF, Schuster, DM. Impact of Clinical Factors on 18F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer. Advances in Radiation Oncology 9(8), 2024. e-Pub 2024. PMID: 39104875.
- Fleming MT, Hermsen R, Purysko AS, Chau A, Davis P, Chapin BF, Schuster DM. True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study. J Nucl Med 65(7):1080-1086, 2024. e-Pub 2024. PMID: 38782456.
- Kuo PH, Esposito G, Ulaner GA, Yoo D, Zukotynski K, Ravizzini GC, Penny R, Miller MP, Chau A, Davis P, Chapin BF, Schuster DM, SPOTLIGHT, groups LS. Interreader and Intrareader Reproducibility of 18F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies. J Nucl Med. e-Pub 2024. PMID: 38871390.
- Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, Chery L, Pisters LL, Ward JF, Gregg JR, Papadopoulos J, Kamat AM, Lozano M, Hoang A, Broom B, Wang X, Huff CD, Logothetis CJ, Troncoso P, Pilié PG, Davis JW. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int. e-Pub 2024. PMID: 38837608.
- Gregg JR, Magill R, Fang AM, Chapin BF, Davis JW, Adibi M, Chéry L, Papadopoulos J, Pettaway C, Pisters L, Ward JF, Hahn AW, Daniel CR, Bhaskaran J, Zhu K, Guerrero M, Zhang M, Troncoso P. The association of body mass index with tumor aggression among men undergoing radical prostatectomy. Urologic Oncology: Seminars and Original Investigations 42(4):116.e1-116.e7, 2024. e-Pub 2024. PMID: 38262868.
- Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer. Journal of Urology 211(4):518-525, 2024. e-Pub 2024. PMID: 38421243.
- Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer. Journal of Urology 211(4):526-532, 2024. e-Pub 2024. PMID: 38421252.
- Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer. Journal of Urology 211(4):509-517, 2024. e-Pub 2024. PMID: 38421253.
- Schaeffer, E, Srinivas, S, Adra, N, An, Y, Bitting, RL, Chapin, BF, Cheng, HH, D'Amico, AV, Desai, NB, Dorff, TB, Eastham, JA, Farrington, TA, Gao, X, Gupta, S, Guzzo, TJ, Ippolito, JE, Karnes, RJ, Kuettel, M, Lang, JM, Lotan, TL, McKay, R, Morgan, TM, Pow-Sang, JM, Reiter, RE, Roach, M, Robin, T, Rosenfeld, S, Shabsigh, A, Spratt, DE, Szmulewitz, R, Teply, BA, Tward, JD, Valicenti, RK, Wong, JK, Snedeker, J, Freedman-Cass, DA. Prostate Cancer, Version 3.2024 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network 22(3):140-150, 2024. e-Pub 2024. PMID: 38626801.
- Kiani K, Kim SP, Pessoa RR, Gershman B, Gonzalez C, Molina E, Warren A, DaSilva RD, Chapin BF, Ballon-Landa E. Association of Frailty and Complications Following Prostate Biopsy. Urology Practice 11(1):117-122, 2024. e-Pub 2024. PMID: 37914379.
- Kiani K, Kim SP, Pessoa RR, Gershman B, Gonzalez C, Molina E, Warren A, DaSilva RD, Chapin B, Ballon-Landa E. Association of Frailty and Complications Following Prostate Biopsy: Results From a Population-Based, Privately Insured Cohort. Urol Pract 11(1):101097UPJ0000000000000476, 2024. e-Pub 2024. PMID: 37914379.
- Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF, Group LS. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer. European urology 84(4):361-370, 2023. e-Pub 2023. PMID: 37414702.
- Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J, Freedman-Cass DA. Prostate Cancer, Version 4.2023. JNCCN Journal of the National Comprehensive Cancer Network 21(10):1067-1096, 2023. e-Pub 2023. PMID: 37856213.
- Andring LM, Abu-Gheida I, Bathala T, Yoder AK, Manzar GS, Maldonado JA, Frank SJ, Choi S, Nguyen QN, Hoffman K, McGuire SE, Mok H, Aparicio A, Chapin BF, Tang C. Definitive local therapy for T4 prostate cancer associated with improved local control and survival. BJU International 132(3):307-313, 2023. e-Pub 2023. PMID: 37057728.
- Wang K, Kumar T, Wang J, Minussi DC, Sei E, Li J, Tran TM, Thennavan A, Hu M, Casasent AK, Xiao Z, Bai S, Yang L, King LM, Shah V, Kristel P, van der Borden CL, Marks JR, Zhao Y, Zurita AJ, Aparicio A, Chapin B, Ye J, Zhang J, Gibbons DL, PRECISION Consortium GC, Sawyer E, Thompson AM, Futreal A, Hwang ES, Wesseling J, Lips EH, Navin NE. Archival single-cell genomics reveals persistent subclones during DCIS progression. Cell 186(18):3968-3982.e15, 2023. e-Pub 2023. PMID: 37586362.
- Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM, Group SS. Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence. Journal of Urology 210(2):299-311, 2023. e-Pub 2023. PMID: 37126069.
- Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer. JAMA Oncology 9(6):825-834, 2023. e-Pub 2023. PMID: 37022702.
- Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SK. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). Journal for immunotherapy of cancer 11(3), 2023. e-Pub 2023. PMID: 36948506.
- Ryckman JM, Thomas TV, Wang M, Wu X, Siva S, Spratt DE, Slotman B, Pal S, Chapin BF, Fitzal F, Soran A, Bex A, Louie AV, Lehrer EJ, Zaorsky NG. Local Treatment of the Primary Tumor for Patients With Metastatic Cancer (PRIME-TX). International Journal of Radiation Oncology Biology Physics 114(5):919-935, 2022. e-Pub 2022. PMID: 35840112.
- Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA. NCCN GUIDELINES® INSIGHTS. JNCCN Journal of the National Comprehensive Cancer Network 20(12):1288-1298, 2022. e-Pub 2022. PMID: 36509074.
- Geskin AA, Westney OL, Graber WJ, Smith III TG, Chapin BF, Gregg JR. Complications Of Peri-Operative Ureteral Catheter Placement. Urology 164:88-93, 2022. e-Pub 2022. PMID: 34280440.
- Ajay, D, Li, H, Barrett-Harlow, BL, Nguyen, JN, Benson, CR, Wang, X, Chapin, BF, Davis, JW, Westney, OL. Perioperative factors contributing to delayed return of continence after radical prostatectomy. Continence 2, 2022. e-Pub 2022.
- Ranasinghe WKB, Troncoso P, Surasi DS, Ibarra Rovira JJ, Bhosale P, Szklaruk J, Kokorovic A, Wang X, Elsheshtawi M, Zhang M, Aparicio A, Chapin BF, Bathala TK. Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI. Radiology 303(1):110-118, 2022. e-Pub 2022. PMID: 35076303.
- Yadav, D, Hwang, H, Qiao, W, Upadhyay, R, Chapin, BF, Tang, C, Aparicio, A, Lopez-Olivo, MA, Kang, SK, Macapinlac, HA, Bathala, TK, Surasi, DS. 18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer. Radiology: Imaging Cancer 4(2), 2022. e-Pub 2022. PMID: 35212559.
- Yadav D, Hwang H, Qiao W, Upadhyay R, Chapin BF, Tang C, Aparicio A, Lopez-Olivio MA, Kang SK, Macapinlac HA, Bathala TK, Surasi DS. 18F-Fluciclovine Versus PSMA PET Imaging in Primary Tumor Detection During Initial Staging of High-Risk Prostate Cancer: A Systemic Review and Meta-Analysis. Radiology: Imaging Cancer, 2022. e-Pub 2022.
- Shapiro, DD, Davis, JW, Williams III, WH, Chapin, BF, Ward, JF, Pettaway, CA, Gregg, JR. Increased body mass index is associated with operative difficulty during robot-assisted radical prostatectomy. BJUI Compass 3(1):68-74, 2022. e-Pub 2022. PMID: 35475154.
- Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. European Journal of Cancer 157:259-267, 2021. e-Pub 2021. PMID: 34536949.
- Altok M, Chapin BF, Matin SF, Achim MF, Gregg JR, Davis JW. Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. Urology 155:144-151, 2021. e-Pub 2021. PMID: 33676955.
- Baiomy A, Schellingerhout D, Chapin BF, Weinberg JS, Raza SM, Macapinlac H, Ravizzini G. Rate of incidental central nervous system meningioma detected in patients undergoing 18F-fluciclovine PET/CT imaging for evaluation of prostate cancer. Nuclear medicine communications 42(7):755-762, 2021. e-Pub 2021. PMID: 33741867.
- Westerman ME, Tabakin AL, Sexton WJ, Chapin BF, Singer EA. Impact of CoVID-19 on resident and fellow education. Urologic Oncology: Seminars and Original Investigations 39(6):357-364, 2021. e-Pub 2021. PMID: 33160843.
- Wilkins LJ, Tosoian JJ, Reichard CA, Sundi D, Ranasinghe W, Alam R, Schwen Z, Reddy C, Allaf M, Davis JW, Chapin BF, Ross AE, Klein EA, Nyame YA. Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy. Cancer 127(9):1425-1431, 2021. e-Pub 2021. PMID: 33721334.
- Tang C, Lei X, Smith GL, Pan HY, Hoffman KE, Kumar R, Chapin BF, Shih YT, Frank SJ, Smith BD. Influence of Geography on Prostate Cancer Treatment. International Journal of Radiation Oncology Biology Physics 109(5):1286-1295, 2021. e-Pub 2021. PMID: 33316361.
- Shapiro DD, Gregg JR, Lim AH, Nogueras-González GM, Choi H, Kang HC, Inguillo IA, Chapin BF, Davis JW, Ward JF. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU International 127(3):340-348, 2021. e-Pub 2021. PMID: 32357283.
- Gregg JR, Zhang X, Chapin BF, Ward JF, Kim J, Davis JW, Daniel CR. Adherence to the Mediterranean diet and grade group progression in localized prostate cancer. Cancer 127(5):720-728, 2021. e-Pub 2021. PMID: 33411364.
- Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. European urology 79(2):298-306, 2021. e-Pub 2021. PMID: 33279304.
- Reichard CA, Kukreja J, Gregg JR, Bathala TK, Achim MF, Wang X, Davis JW, Nguyen QN, Chapin BF. Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging. European Urology Focus 7(1):71-77, 2021. e-Pub 2021. PMID: 31076357.
- Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced Prostate Cancer. Journal of Urology 205(1):22-29, 2021. e-Pub 2021. PMID: 32960678.
- Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced Prostate Cancer. Journal of Urology 205(1):14-21, 2021. e-Pub 2021. PMID: 32960679.
- Hussain M, Lin D, Saad F, Vapiwala N, Chapin BF, Sandler H, Evans CP, Carducci MA, Sachdev S. Newly diagnosed high-risk prostate cancer in an era of rapidly evolving new imaging. Journal of Clinical Oncology 39(1):13-16, 2021. e-Pub 2021. PMID: 33048621.
Review Articles
- MacDonald, LP, Fang, A, Tang, C, Chapin, BF. Current and Upcoming Trials in Localized Prostate Cancer. Urologic Clinics of North America 53(1):171-181, 2026. e-Pub 2026. PMID: 41265999.
- Shi X, Wang JH, Chapin BF, Aparicio A, Subudhi SK, Tran PT, Park RJ, Deek MP, Zhang H, Bylund KC, Cummings M, Armstrong AJ, Tang C, Sutera P. Integrating systemic therapy and metastasis-directed therapy in oligometastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis 29(2):282-291, 2025. e-Pub 2025. PMID: 41076453.
- Fang, A, Frigo, DE, Hahn, AW, Razouki, ZA, Hwang, J, Koutroumpakis, E, Lawen, T, Smith, MR, Hamilton-Reeves, J, DiGiovanni, J, Higgason, N, Garcia, RS, Chapin, BF, Pettaway, CA, Chery, LJ, Troncoso, P, Logothetis, CJ, Daniel-MacDougall, CR, Wei, P, Gregg, JR. GLP-1 Agonist Use Among Men With Localized Prostate Cancer. Urology 201:152-158, 2025. e-Pub 2025. PMID: 40348027.
- Rais-Bahrami, S, Davis, P, Chau, A, Galgano, SJ, Chapin, BF, Schuster, DM, Turnbull, CM. Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer. Diagnostics 15(10), 2025. e-Pub 2025. PMID: 40428217.
- Fang, A, MacDonald, LP, Gregg, JR, Siddiqui, BA, Tang, C, Chapin, BF. Prostatectomy and other local treatments for oligometastatic prostate cancer. Current opinion in urology 35(2):171-177, 2025. e-Pub 2025. PMID: 39604252.
- Fang, A, Gregg, JR, Pettaway, CA, Ma, J, Szklaruk, J, Bathala, TK, Surasi, DS, Chapin, BF. Whole-body MRI for staging prostate cancer. BJU International 135(1):13-21, 2025. e-Pub 2025. PMID: 39308142.
- Fang AM, Jackson J, Gregg JR, Chery L, Tang C, Surasi DS, Siddiqui BA, Soroush-Rais-Bahrami, Bathala T, Chapin BF. Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Current treatment options in oncology 25(1):66-83, 2024. e-Pub 2024. PMID: 38212510.
- Klaassen Z, Scarpato KR, Ristau BT, Stratton KL, Porten SP, Smaldone MC, Chapin BF, Psutka SP. Research highlights of the 2020 society of urologic oncology young urologic oncologists’ program. Urologic Oncology: Seminars and Original Investigations 39(8):452-454, 2021. e-Pub 2021. PMID: 33858748.
- Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF. Optimizing the diagnosis and management of ductal prostate cancer. Nature Reviews Urology 18(6):337-358, 2021. e-Pub 2021. PMID: 33824525.
- McCormick BZ, Chery L, Chapin BF. Contemporary outcomes following robotic prostatectomy for locally advanced and metastatic prostate cancer. Translational Andrology and Urology 10(5):2178-2187, 2021. e-Pub 2021. PMID: 34159100.
Professional Educational Materials
- Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, Chapin B, Cheng HH, Cho SY, D’Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Ippolito JE, Karnes R, Kishan A, Kuettel MR, Lang JM, Lee D, Lotan T, McDonald A, Morgan T, Pessoa R, Rais-Bahrami S, Roach M, Robin T, Rosenfeld S, Scarpato KR, Shabsigh A, Szmulewitz R, Teply BA, Tward J, Valicenti R, VanderWeele D, Wong JK, Kovach E, Freedman-Cass AD. NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(11):469-493, 2025.
- Chapin BF. AUA Advanced Prostate Cancer Guidelines - Salvage, 2022.
Other Articles
- Boesen, L, Chapin, BF Re. European urology 86(5):479-480, 2024. PMID: 39043550.
- Fang AM, Jackson J, Gregg JR, Chery L, Tang C, Surasi DS, Siddiqui BA, Rais-Bahrami S, Bathala T, Chapin BF Correction to. Current treatment options in oncology 25(5):617-618, 2024. PMID: 38642282.
- Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men with Suspected Prostate Cancer Recurrence. Journal of Urology 210(3):411-412, 2023. PMID: 37350185.
- Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM Reply by Authors. Journal of Urology 210(2):310-311, 2023. PMID: 37416959.
Editorials
- Kronstedt S, Rice K, Faiena I, Chapin BF. The Critical Difference Between Understanding and Consent: Lessons From Germline and Somatic Testing for Metastatic Prostate Cancer. JCO Oncol Pract 43:OP2500564, 2025. PMID: 40997281.
- Andrews JR, Sood A, Chapin BF. Point-Counterpoint. Journal of Urology 210(2):242-243, 2023. PMID: 37194136.
- Cooperberg MR, Lin DW, Morgan TM, Chapin BF, Chen RC, Eggener SE. Active Surveillance. Journal of Urology 207(2):262-264, 2022. PMID: 34775795.
Abstracts
- Westerman M, Bree K, Mantaring C, Rukundo I, Garcia-Gonzalez M, Lafleur A, Best R, Dinney C, Kamat A, Navai N, Pisters L, Wood C, Karam J, Papadopoulos J, Chery L, Mehrad A, Chapin B, Ward J, Pettaway C, Davis J, Gregg J, Graber W, Smith T, Westney OL, Valle D, Crump L, Varghese R, Saucedo M, Cunningham J, Casteel K, Matin S. Apixaban Versus Enoxaparin For Post-Surgical Extended Duration VTE Prophylaxis: A Perspective Quality Improvement Study. American Urologic Association Annual Meeting, 2022. e-Pub 2022.
- Pieretti A, Kang H, Choi H, Zhang M, Chapin B, Ward J, Troncoso P, Gregg J. Using Magnetic Resonance Imaging to Define Focal Therapy Templates in Patients With Intermediate-Risk Prostate Cancer. American Urologic Association Annual Meeting, 2022. e-Pub 2022.
- Kennady IV EH, Kang HC, Choi H, Akorede A, Davis JW, Pisters LL, Pettaway C, Chapin BF, Ward JF, Gregg JR. Determining Clinical Outcomes Among Men With A High-Risk Prostate MRI and Negative Fusion Biopsy. 22nd Annual Meeting at the Society of Urologic Oncology (SUO), 2021. e-Pub 2021.
- Geskin A, Westney OL, Graber W, Smith T, Chapin B, Gregg J. Complications of Peri-Operative Ureteral Catheter Placement: Experience at a Major Cancer Center. South Central Section of the American Urological Association (SCS AUA), 2021. e-Pub 2021.
- Blum K, Ward J, Chapin B, Zhang M, Troncoso P, Gregg J. Focal Therapy for Intermediate Risk Prostate Cancer: Patient Selection Using MRI/US Fusion Biopsy Criteria. South Central Section of the American Urologic Association (SCS AUA), 2021. e-Pub 2021.
- Gregg J, Fahrman J, Wu R, Murage E, Dennison J, Chapin, B, Davis J, Wei P, Hanash S, and Daniel C. Association of Baseline Plasma Caffeine Levels and Related Metabolites With Time to Grade Group Progression in Men With Prostate Cancer on Active Surveillance. Journal of Urology, American Urologic Association Annual Meeting 206(Supplement 3):e571-e571, 2021. e-Pub 2021.
- Davis J, Chapin B, Pettaway C, Chery L, Pisters L, Ward J, Papadopoulos J, Kamat A, Lozano M, Troncoso P, and Logothetis C. A Phase II Study of 6-Months Apalutamide Prior to Radical Prostatectomy in Intermediate Risk Patients to Redue the Frequency of Pathologic Features That Drive Post-Operative Radiation Therapy. Journal of Urology, American Urologic Association Annual Meeting 206(Supplement 3):e1070-e1071, 2021. e-Pub 2021.
Book Chapters
- Ranasinghe, WK, Chapin, BF. Preclinical, 25-29, 2024.
- Chapin BF. Positive Surgical Margins: How to Self-Evaluate and Improve. In: Robot-Assisted Radical Prostatectomy: Beyond the Learning Curve. Springer.
Letters to the Editor
- Oke O, Ranasinghe W, Tang C, Shaaban S, Xiao L, Reichard CA, Anscher MS, Chapin BF, Aparicio A. Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma. European urology 80: 389-390, 2021.
Patient Reviews
CV information above last modified September 10, 2026